VEGF-C level as a predictor of pelvic lymph node metastases of cervical cancer at early stage

  • Andrijono Andrijono
  • Heru Priyanto
DOI: https://doi.org/10.13181/mji.v18i4.372
Keywords: cervical cancer, metastatis, VEGF
Abstract viewed: 595 times
PDF downloaded: 421 times

Abstract

Aim Vascular endothelial growth factor (VEGF) works to stimulate angiogenesis and lymphogenesis which is one of the factors in the metastasis process. This study aimed to identify whether VEGF level could be used to predict metastasis into pelvic lymph node of stage IB-IIA cervical cancer.

Methods The study was case control study, a case (cervical cancer metastasis into pelvic lymph node), a control (cervical cancer without metastasis). Independent variables included primary lesion size, histological type, grade of cell differentiation, lymph vascular space involvement, and VEGF level. Dependent variable was metastasis into pelvic lymph node.

Results Based on cut-off point, VEGF-C serum level, i.e., 10,066.90 pg/ml, 11/47 patients or 23.41%, had the level above that value, and 10/11 of the group of patient or 90.91% were found to develop metastasis into pelvic lymph node. Sensitivity of the examination of VEGF-C level in relation to the risk for the incidence of lymph node in this study was 71.43%, with a specificity of 96.97%, positive predictive value (PPV) of 90.91%, and negative predictive value (NPV) of 88.89%.

Conclusion: VEGF-C level in the serum could be used to predict lymph node metastasis of stage IB-IIA cervical cancer, with a sensitivity of 71.43% and specificity of 96.97%. (Med J Indones 2009; 18: 257-61)

References

  1. DiSaia PJ, Creasman WT. Clinical Gynecologic Oncology. Sixth edition. Mosby Inc, Missouri.2002;53-112.

  2. Sevin BU, Nadji M, Lampe BY, Hilsenbek S, Koechli OR, Averette HE. Prognostic factors of early stage cervical cancer treated by radical hysterectomy. Cancer. 1995;76:1978-86.

  3. Pieterse QD, Trimbos JBMZ, Dijkman A, Creutzberg CL, Gaarentstroom KN, Peters AAW, Kenter GG. Postoperativeradiation therapy improves prognosis in patients with adverse risk factors in localized, early-stage cervical cancer : a retrospective comparative study. Int J Gynecol Cancer 2006;16:1112-8.

  4. Micha JP, Goldstein BH, Rettenmaier MA, Brown JV, John CR, Markman M. Surgery alone or surgery with a combination radiation or chemoradiation of management of patients with bulky-stage IB2 cervical carcinoma. Int J Gynecol Cancer. 2006;16:1147-51.

  5. Zola P, Landoni F, Torri W, Buda A, Mazzola S. Randomised controlled trial of adjuvant treatment in early cervical cancer. 13th International Meeting of ESGO, Brussel, 2003 April 6-10.

  6. Kodama J, Seki N, Tokumo K, Hongo A, Miyagi Y, Yoshinouchi M, et al. Vascular endothelial growth factor is implicated in early invasion in cervical cancer. Euro J of Cancer.1999;35(3):485-9.

  7. Lee KBM, Lee JM, Park CJ, Lee KB, Cho HY, Ha SY. Lymph node metastasis and lymph vascular space invasion in microinvasive squamous cell carcinoma of the uterine cervix. Int J Gyn Cancer.2006;16(3):1184-7.

  8. Hashimoto I, Kodama J, Seki N, Hongo A, Yoshinouchi M, Okuda H, et al. Vascular endothelial growth factor-C expression and its relationship to pelvic lymph node status in invasive cervical cancer. British J of Cancer. 2001;85:93-7.

  9. Detmar M, Hirakawa S. The formation of lymphatic vessel and its importance in the setting of malignancy. Th J of Exp Med.2002;196(6):713-8.

  10. Pinedo HM, Slamon DJ. Translational Research: The role of VEGF in tumor angiogenesis. The Oncologist. 2000;5(1):1-2.

  11. Stacker SA, Baldwin ME, Achen MG. The role of tumor lymphangiogenesis in metastatic spread. The Faseb J. 2002;16 July:922-34.

Published
2009-11-01
How to Cite
1.
Andrijono A, Priyanto H. VEGF-C level as a predictor of pelvic lymph node metastases of cervical cancer at early stage. Med J Indones [Internet]. 2009Nov.1 [cited 2024Apr.26];18(4):257-61. Available from: http://mji.ui.ac.id/journal/index.php/mji/article/view/372
Issue
Vol. 18 No. 4 (2009): October-December
Section
Clinical Research

Copyright (c) 2009 Andrijono Andrijono, Heru Priyanto

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with Medical Journal of Indonesia agree to the following terms:

  1. Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
  2. Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.

Most read articles by the same author(s)